Core Viewpoint - The global first innovative drug, Hydrochloride Tazemetostat, was withdrawn from the market due to safety concerns, highlighting the risks associated with innovative drug approvals in the industry [1][2]. Group 1: Drug Withdrawal Details - Hydrochloride Tazemetostat was approved conditionally in China in March 2025 for treating eligible lymphoma patients but was announced for withdrawal on March 9, 2023, due to potential risks of secondary hematologic malignancies [2][3]. - The withdrawal was based on new data from ongoing clinical trials suggesting that the risks of secondary malignancies outweighed the potential benefits of the treatment [6][12]. - The drug had previously filled clinical gaps, being the first approved treatment for certain rare cancers, including epithelioid sarcoma and EZH2 mutation-positive follicular lymphoma [3][9]. Group 2: Patient Impact and Market Response - The affected patient population is expected to be small, as the drug's sales were projected to be limited, with an estimated revenue of $90,000 in 2024 and $250,000 in 2025 [4][15]. - The drug's high cost, approximately 38,700 yuan per month, further limits its patient base [14]. - Following the withdrawal, the National Healthcare Security Administration removed the drug from the commercial insurance innovation drug directory [4]. Group 3: Clinical and Regulatory Insights - The drug was initially approved through expedited regulatory pathways due to urgent clinical needs, allowing for conditional market entry while requiring ongoing clinical trials to confirm efficacy and safety [11][12]. - The emergence of secondary malignancies as a side effect necessitates a reevaluation of the risk-benefit ratio for drugs approved under similar conditions [12][16]. - The case raises questions about whether conditionally approved drugs should be included in insurance directories, emphasizing the need for long-term safety and efficacy data before formal approval [16][17].